Holiday Coverage - The CCTG Central Office will be closed on Canada Day, Wednesday, July 1st and will be open with coverage of critical activities on Thursday July 2nd and Friday July 3rd due to Queen's University wide holidays. All regular web-based applications (i.e. MANGO, GCP) will continue to be available. Regular business hours will resume on Monday, July 6 at 8:30 am EST. Have a safe and Happy Canada Day!

Wednesday, July 1 - CLOSED | Thursday, July 2 - OPEN - 9:00am – 5:00pm (limited coverage team) | Friday, July 3 - OPEN - 9:00am – 5:00pm (limited coverage team)

  For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

IND.231 presented at the Targeted Anti-Cancer Therapies (TAT) International Congress 2018

Wednesday, March 14, 2018
Dr. John Hilton, the Study Co-Chair of IND.231, gave an oral presentation

Dr. John Hilton, the Study Co-Chair of IND.231, gave an oral presentation of the results to date from IND.231, A Phase I/II Study of CX-5461, at the Targeted Anti-Cancer Therapies (TAT) International Congress 2018 - "the home of phase I in oncology". The conference was held in Paris, France on March 5-7, 2018.

TAT focuses on early-phase development and translational research. The programme covers targeted agents, immuno-oncology and combinations involving such agents.

You can read more about the results of this study and find a link to the abstract by using this link ... https://academic.oup.com/annonc/article/29/suppl_3/mdy048.003/4917515?searchresult=1


CCTG IND.231: A phase 1 trial evaluating CX-5461 in patients with advanced solid tumors

Background: G-quadruplexes are secondary DNA structures that reversibly form in guanine-rich regions that can lead to replication fork collapse and double-stranded DNA breaks. Preclinical work by our group has demonstrated that CX-5461 can stabilize G-quadruplexes, resulting in synthetic lethality in BRCA1/2 deficient cell lines and xenograft models.

Methods: We conducted a phase I study of 7 dose levels of CX-5461 (DLs: 50, 100, 150, 200, 250, 325, 475 mg/m2) administered intravenously on days 1 and 8 of a 4-week cycle in patients with advanced solid tumors with a PS 0-2 and adequate organ function using a 3 + 3 design. Patients were treated until disease progression. The primary objective was the determination of RP2D. The DLT evaluation period was cycle 1 and AEs needed to be maximally managed (i.e diarrhea, phototoxicity, nausea/vomiting) to be considered a DLT. Secondary objectives include ORR (RECIST 1.1), PK, and toxicity (CTCAEv4.0).